CRISPR Therapeutics
CRSP
310 hedge funds and large institutions have $4B invested in CRISPR Therapeutics in 2020 Q3 according to their latest regulatory filings, with 69 funds opening new positions, 96 increasing their positions, 86 reducing their positions, and 32 closing their positions.
116% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 32
50% more funds holding in top 10
Funds holding in top 10: 6 → 9 (+3)
38% more capital invested
Capital invested by funds: $2.91B → $4B (+$1.1B)
12% more funds holding
Funds holding: 276 → 310 (+34)
12% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 86
3.78% more ownership
Funds ownership: 64.46% → 68.24% (+3.8%)
3% less call options, than puts
Call options by funds: $64.7M | Put options by funds: $66.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$607M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$175M |
| 3 |
PA
Perceptive Advisors
New York
|
+$119M |
| 4 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$25.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$22.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
-$48.9M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$44.4M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$38.7M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$27.5M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$26.5M |
CRSP Hedge Fund Activity: Q3 2020 in Review
310 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q3 2020, worth a combined $4B — up 38% from $2.91B a quarter earlier.
Buyers outnumbered sellers: 69 funds opened new CRSP positions and 32 closed out — a net gain of 37 holders — while 96 added to existing stakes and 86 trimmed.
The largest buyer was Capital International Investors, adding an estimated $607M. The largest seller was Versant Venture Management, cutting an estimated $48.9M.
- 310 institutional investors held CRISPR Therapeutics (CRSP) as of Q3 2020, up from 276 in Q2 2020.
- Funds reported $4B of CRISPR Therapeutics stock for Q3 2020, up 38% quarter-over-quarter.
- 69 funds opened new CRISPR Therapeutics positions in Q3 2020 and 32 closed out, a net change of +37 holders.
- The largest CRISPR Therapeutics buyer in Q3 2020 was Capital International Investors, an estimated $607M added.
- The largest CRISPR Therapeutics seller in Q3 2020 was Versant Venture Management, an estimated $48.9M sold.
Based on aggregated 13F filings for Q3 2020.